SPA
AMRX icon

Sherbrooke Park Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Sherbrooke Park Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,300
Closed -$180K – 514
2025
Q2 		$180K Buy
+22,300
New +$168K 0.08% 408
2025
Q1 		– Sell
-12,274
Closed -$97.2K – 590
2024
Q4 		$97.2K Sell
12,274
-54,293
-82% -$455K 0.03% 674
2024
Q3 		$554K Buy
+66,567
New +$521K 0.13% 272
2023
Q4 		– Sell
-12,822
Closed -$54.1K – 454
2023
Q3 		$54.1K Buy
+12,822
New +$47.8K 0.02% 486

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Sherbrooke Park Advisers's AMRX Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 22,300 shares — an estimated $180K sold.

Sherbrooke Park Advisers first reported a position in AMRX in Q3 2023 and held it in 4 quarters. The position peaked at $554K in Q3 2024. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 22,300 Amneal Pharmaceuticals shares in Q3 2025, an estimated $180K.
  • Sherbrooke Park Advisers first reported a position in Amneal Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Amneal Pharmaceuticals position peaked at $554K in Q3 2024.
  • 248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.